methylphenidate

(redirected from Equasym)
Also found in: Dictionary, Thesaurus, Wikipedia.
Related to Equasym: Equasym XL

methylphenidate

 [meth″il-fenĭ-dāt]
a mild central nervous system stimulant; the hydrochloride salt is administered orally in the treatment of attention-deficit/hyperactivity disorder and narcolepsy.

methylphenidate

/meth·yl·phen·i·date/ (meth″il-fen´ĭ-dāt) a central stimulant, used in the form of the hydrochloride salt in the treatment of attention-deficit in children and narcolepsy.

methylphenidate

(mĕth′əl-fĕn′ĭ-dāt′, -fē′nĭ-)
n.
A drug, C14H19NO2, chemically related to amphetamine, that acts as a mild stimulant of the central nervous system and is used in its hydrochloride form to treat attention deficit hyperactivity disorder and narcolepsy.

methylphenidate

An amphetamine-derived CNS stimulant.
 
Adverse effects
Decreased appetite—10–15% of children have major weight loss; insomnia—most suffer sleep delay; abdominal pain; headaches; dry mouth; dizziness; depression, tachycardia; a proposed link to decreased growth is uncertain.
 
Indications for
Hyperactivity, ADD, childhood narcolepsy.

methylphenidate

Ritalin® Neuropharmacology An amphetamine derived CNS stimulant used to control ADD and hyperactivity in children Adverse effects ↓ Appetite, 10-15% of children have major weight loss; insomnia–most suffer sleep delay, abdominal pain, headaches, dry mouth, dizziness, depression, tachycardia; link with ↓ growth is uncertain Used for Hyperactivity; narcolepsy; ADD. See Amphetamine.

methylphenidate

A nervous system stimulant drug that, paradoxically, has been found effective in the management of ATTENTION-DEFICIT HYPERACTIVITY DISORDER in children. A brand name is Ritalin. The current consensus of opinion on the use of this drug for this purpose is that it is grossly over-prescribed, especially in the USA.

methylphenidate

a central nervous system stimulant used in the treatment of hyperkinesis and narcolepsy in dogs.
References in periodicals archive ?
9 million), offset by an adjustment to contingent consideration payable for EQUASYM ($8.
b) Acquisitions & integration activities: Integration and transaction related costs in respect of the acquisition of Jerini and EQUASYM ($1.
Following the acquisition of EQUASYM from UCB on March 31, 2009 the Company has recorded product sales of EQUASYM for the three months to June 30, 2009 of $4.
3 million (2008: $nil) relating to the integration of Jerini AG and charges associated with the acquisition of EQUASYM.
b) Acquisitions & integration activities:Costs associated with acquisition of EQUASYM ($0.
Acquisition of EQUASYM IR and XL - On March 31, 2009 the Company completed the acquisition from UCB S.
Strong cash inflows from operating activities and cash received on the disposal of Shire's minority interest in Virochem have been partially offset by cash outflows from the acquisition of EQUASYM from UCB ($72.
the continued roll-out of FOSRENOL, EQUASYM and RESOLOR in EU and RoW countries.
In 2009, Shire acquired the worldwide rights (excluding the US, Canada and Barbados) to EQUASYM IR and XL from UCB and entered into a research collaboration with Santaris Pharma A/S ('Santaris') for the development of its Locked Nucleic Acid ('LNA') drug platform technology.
EQUASYM will allow Shire to build on its status as the leader in the United States ADHD market with patients and customers in Europe, and establishes a solid bridge for Shire's other ADHD treatments, including VYVANSE(TM) (lisdexamfetamine dimesylate), its flagship ADHD product, in territories outside of the United States.
EQUASYM will allow Shire to build on its status as the leader in the United States ADHD market with patients and customers in Europe and establishes a solid bridge for Shire's other ADHD treatments in territories outside of the United States.
The acquisition in 2005 of TKT (and the consequent establishment of our HGT business) and the acquisition of EQUASYM in 2009 (which facilitated immediate access to the European ADHD market) provided Shire with the platforms to increase its presence in Europe and the rest of the world ('RoW'), thereby working towards diversifying the risk associated with being reliant on one geographic market.